

Creo Medical Group plc

Significant Shareholders¹

Name of shareholder	Number of shares	Voting rights (%)
Canaccord Genuity ²	39,220,314	10.85
M&G Investments	33,305,594	9.21
Baillie Gifford	22,296,687	6.17
Hargreaves Lansdown, stockbrokers (EO)	17,878,392	4.95
Amati Global Investors	16,998,915	4.70
River Global Investors	15,988,094	4.42
AXA Framlington Investment Managers	15,252,080	4.22
Finance Wales Investments	14,376,727	3.98

Director Shareholdings (excluding options) as at 30 June 2024³

Director	Number of shares	Voting rights (%)
Kevin T. Crofton	650,000	0.18
John Bradshaw	1,371,082	0.38
Ivonne Cantu	125,000	0.03
Craig Gulliford ⁴	1,644,527	0.45
Mr Richard Rees	2,819,963	0.78
Prof. Christopher Hancock	4,816,413	1.33
David Woods	440,255	0.12
Total	11,867,240	3.27

Percentage of AIM Securities not in public hands⁵ as at 30 June 2024: 21.56%

Last updated 25 July 2024

¹ Information obtained from an analysis of Creo Medical's share register (dated 30 June 2024) undertaken on behalf of Creo Medical by Equiniti - RD:ID.

² Canaccord Genuity Wealth Management (Inst) – 34,800,000- 9.63%; Canaccord Genuity Wealth Management (ND) - 4,420,314 - 1.22%.

³ States directors in office from 1 July 2024

⁴ Includes 1,000,000 shares held by Craig Gulliford's wife.

⁵ Shares not held in public hands is calculated as defined in the AIM Rules for Companies including shares held by related parties together with their associates (each as defined in the AIM Rules for Companies) and shares held by trustees of the Company's employee share schemes.